These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 16460487)

  • 1. Long-term monitoring of platelet count, as a non-invasive marker of hepatic fibrosis progression and/or regression in patients with chronic hepatitis C after interferon therapy.
    Taniguchi H; Iwasaki Y; Fujiwara A; Sakaguchi K; Moriya A; Yu PC; Takaki A; Fujioka S; Shimomura H; Shiratori Y
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):281-7. PubMed ID: 16460487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in antipyrine clearance and platelet count, but not conventional liver tests, correlate with fibrotic change in chronic hepatitis C: value for predicting fibrotic progression.
    Coverdale SA; Samarasinghe DA; Lin R; Kench J; Byth K; Khan MH; Crewe E; Liddle C; George J; Farrell GC
    Am J Gastroenterol; 2003 Jun; 98(6):1384-90. PubMed ID: 12818285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy.
    Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Suzuki F; Akuta N; Someya T; Hosaka T; Kobayashi M; Kumada H
    J Gastroenterol; 2004; 39(5):455-60. PubMed ID: 15175944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up study of sustained biochemical responders with interferon therapy.
    Shindo M; Hamada K; Oda Y; Okuno T
    Hepatology; 2001 May; 33(5):1299-302. PubMed ID: 11343259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal changes of the laboratory data of chronic hepatitis C patients with sustained virological response on long-term follow-up.
    Maruoka D; Imazeki F; Arai M; Kanda T; Fujiwara K; Yokosuka O
    J Viral Hepat; 2012 Feb; 19(2):e97-104. PubMed ID: 22239532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis.
    Roche B; Sebagh M; Canfora ML; Antonini T; Roque-Afonso AM; Delvart V; Saliba F; Duclos-Vallee JC; Castaing D; Samuel D
    Liver Transpl; 2008 Dec; 14(12):1766-77. PubMed ID: 19025933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy.
    Moriyama M; Matsumura H; Aoki H; Shimizu T; Yamagami H; Shioda A; Kaneko M; Goto I; Tanaka N; Arakawa Y
    Liver Int; 2005 Feb; 25(1):85-90. PubMed ID: 15698403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
    Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
    Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy.
    Shiffman ML; Stewart CA; Hofmann CM; Contos MJ; Luketic VA; Sterling RK; Sanyal AJ
    J Infect Dis; 2000 Dec; 182(6):1595-601. PubMed ID: 11069229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of long-term interferon therapy for refractory chronic hepatitis c: preventive effect on hepatocarcinogenesis.
    Saito Y; Saito H; Tada S; Nakamoto N; Horikawa H; Kurita S; Kitamura K; Ebinuma H; Ishii H; Hibi T
    Hepatogastroenterology; 2005; 52(65):1491-6. PubMed ID: 16201104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults.
    Sulkowski MS; Mehta SH; Torbenson MS; Higgins Y; Brinkley SC; de Oca RM; Moore RD; Afdhal NH; Thomas DL
    AIDS; 2007 Oct; 21(16):2209-16. PubMed ID: 18090048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Necessities of interferon therapy in elderly patients with chronic hepatitis C.
    Ikeda K; Arase Y; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Kumada H
    Am J Med; 2009 May; 122(5):479-86. PubMed ID: 19375558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term evaluation of interferon therapy in hepatitis C virus-associated cirrhosis: does IFN prevent development of hepatocellular carcinoma?
    Tanaka K; Sata M; Uchimura Y; Suzuki H; Tanikawa K
    Oncol Rep; 1998; 5(1):205-8. PubMed ID: 9458323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis.
    Sanyal AJ; Fontana RJ; Di Bisceglie AM; Everhart JE; Doherty MC; Everson GT; Donovan JA; Malet PF; Mehta S; Sheikh MY; Reid AE; Ghany MG; Gretch DR; Halt-C Trial Group
    Gastrointest Endosc; 2006 Dec; 64(6):855-64. PubMed ID: 17140886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of interferon-treated chronic hepatitis C and serum hepatic fibrosis markers.
    Ueno T; Ide T; Hashimoto O; Uchimura Y; Torimura T; Kumashiro R; Inuzuka S; Sata M
    Hepatogastroenterology; 2001; 48(40):1124-8. PubMed ID: 11490815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there any non-invasive marker replace the needle liver biopsy predictive for liver fibrosis, in patients with chronic hepatitis?
    Vardar R; Vardar E; Demiri S; Sayhan SE; Bayol U; Yildiz C; Postaci H
    Hepatogastroenterology; 2009; 56(94-95):1459-65. PubMed ID: 19950810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C.
    Maylin S; Martinot-Peignoux M; Moucari R; Boyer N; Ripault MP; Cazals-Hatem D; Giuily N; Castelnau C; Cardoso AC; Asselah T; Féray C; Nicolas-Chanoine MH; Bedossa P; Marcellin P
    Gastroenterology; 2008 Sep; 135(3):821-9. PubMed ID: 18593587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B.
    Di Martino V; Thevenot T; Colin JF; Boyer N; Martinot M; Degos F; Coulaud JP; Vilde JL; Vachon F; Degott C; Valla D; Marcellin P
    Gastroenterology; 2002 Dec; 123(6):1812-22. PubMed ID: 12454838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative analysis of liver fibrosis and stellate cell changes in patients with chronic hepatitis C after interferon therapy.
    Sakaida I; Nagatomi A; Hironaka K; Uchida K; Okita K
    Am J Gastroenterol; 1999 Feb; 94(2):489-96. PubMed ID: 10022652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.